Hi everyone,
My name’s Kira and I work in the Policy, Evidence and Influencing team at Breast Cancer Now.
Following its approval for use by NICE on NHS England, we’re looking to hear from anyone who has received the treatment capivasertib in combination with fulvestrant for treating hormone receptor positive, HER-2 negative secondary breast cancer after endocrine therapy. You may have also received it as part of a clinical trial.
The combination is being assessed by the Scottish Medicines Consortium (SMC) to see if it should be made available through NHSScotland. We would love to hear your views to help shape our submission, so we can try make this treatment available across the whole of the UK.
It’s crucial that the SMC hears the voices of patients as part of their assessment. If you’d like to share your views on this treatment, please email policy@breastcancernow.org. Your views will be shared completely anonymously.
Thank you!
Kira